Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  thiotepa
Find trials that include:  Any drugs shown
Results 1-22 of 22 for your search:
Start Over
Iobenguane I-131 or Crizotinib and Standard Therapy in Treating Younger Patients with Newly-Diagnosed High-Risk Neuroblastoma or Ganglioneuroblastoma
Status: Not yet active
Phase: Phase III
Type: Treatment
Age: 365 days to 30 years
Trial IDs: ANBL1531, NCI-2016-01734, NCT03126916
Partially-Matched Donor Stem Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Not specified
Trial IDs: SCT 0813, NCI-2015-00141, CMH SCT 0813, CMH 13H11, NCT02053545
CD34+ Stem Cell Selection in Preventing Graft-Versus-Host Disease in Younger Patients with Malignant Disease Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II, Phase I
Type: Treatment
Age: Under 22
Trial IDs: AAAK8060, NCI-2014-00137, NCT02061800
Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Treatment
Age: 10 to 69
Trial IDs: MT2005-21, NCI-2010-01700, 2006LS032, UMN-2006LS032, UMN-MT2005-21, UMN-0608M90586, NCT00432094
Mismatched Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 65 and under
Trial IDs: IUCRO-0184, NCI-2011-02351, NCT00593554
Cyclophosphamide in Treating Patients with Hematological Malignancies after Undergoing Donor Stem Cell Transplant
Status: Active
Phase: Phase II
Type: Supportive care, Treatment
Age: 18 and over
Trial IDs: 11D.51, NCI-2011-02342, 2010-54, NCT01349101
Reduced Intensity Donor Stem Cell Transplant in Treating Patients with Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11D.247, NCI-2011-02345, 2011-31, 1795, NCT01384513
Reduced-Intensity Conditioning before Donor Stem Cell Transplant in Treating Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 12D.501, NCI-2012-02762, 2012-67, NCT01760655
Donor Progenitor Cell and Natural Kill Cell Transplant in Treating Younger Patients with High-Risk Hematologic Malignancies
Status: Active
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: HAPNK1, NCI-2013-00609, NCT01807611
Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts from HLA-Matched Related and Unrelated Donors in Preventing GVHD
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 14 to 60
Trial IDs: 2684.00, NCI-2014-01301, NCT02220985
Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Recurrent or Progressive Germ Cell Tumors
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: Not specified
Trial IDs: CCI-09-00196, NCI-2013-01195, NCT01270742
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients with High-Risk Neuroblastoma
Status: Active
Phase: Phase II
Type: Treatment
Age: 29 and under
Trial IDs: 2015LS108, NCI-2015-02023, MT2015-25, NCT02605421
Blinatumomab and T Cell Depleted Donor Blood Cell Transplant in Treating Younger Patients with Relapsed or Refractory Hematologic Malignancy after a Previous Transplant
Status: Temporarily closed
Phase: Phase II
Type: Treatment
Age: 21 and under
Trial IDs: REF2HCT, NCI-2016-00812, NCT02790515
Busulfan, Fludarabine Phosphate, and Post-Transplant Cyclophosphamide in Treating Patients with Blood Cancer Undergoing Donor Stem Cell Transplantation
Status: Active
Phase: Phase II
Type: Treatment
Age: 12 to 65
Trial IDs: 2016-0137, NCI-2017-00614, NCT02861417
Genetically Modified Donor Stem Cell Transplant Followed by Zoledronic Acid in Treating Younger Patients with Relapsed/Refractory Hematologic Malignancies or High Risk Solid Tumors
Status: Active
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 7 months to 21 years
Trial IDs: UW13090, NCI-2015-01163, NCT02508038
Donor Peripheral Blood Stem Cell Transplant in Treating Patients with Hematological Malignancies
Status: Active
Phase: No phase specified
Type: Treatment
Age: 0 to 19
Trial IDs: 12-053, NCI-2012-00822, NCT01598025
Partially HLA-Mismatched Related Donor Stem Cell Transplant Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection in Treating Patients with Hematologic Malignancies
Status: Active
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 16-1237, NCI-2016-01572, NCT02880293
Standard Chemotherapy in Treating Young Patients with Medulloblastoma or Other Central Nervous System Primitive Neuro-ectodermal Tumors
Status: Active
Phase: No phase specified
Type: Treatment
Age: 9 and under
Trial IDs: NCH-15004, NCI-2016-01993, IRB15-00399, NCT02875314
Start Over